SCHEMBL9892497

SCHEMBL9892497

Cc1ccc(N=O)c(C#N)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
GAA P10253 1/20 0.38
CYP2A6 P11509 1/20 0.37
FFAR1 O14842 1/20 0.36
AR P10275 5/20 0.35
MCL1 Q07820 1/20 0.35
TSHR P16473 2/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
PKM P14618 1/20 0.34
GRM2 Q14416 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
USP8 P40818 1/20 0.33
USP7 Q93009 1/20 0.33
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28254037 0.84 AR (0.39) KDM4EALDH1A1HPGDGAACYP2A6
SCHEMBL17027553 0.81 CYP3A4 (0.42) KDM4EALDH1A1HPGDGAACYP2A6
SCHEMBL11878247 0.81 HTR3E (0.44) KDM4EALDH1A1HPGDGAACYP2A6
SCHEMBL13073880 0.76 TRPV4 (0.34) KDM4EALDH1A1HPGDFFAR1AR
SCHEMBL12990596 0.76 KDM4E (0.47) KDM4EALDH1A1HPGDGAAMCL1
SCHEMBL1003862 0.73 ALDH1A1 (0.46) KDM4EALDH1A1CYP2A6FFAR1AR
SCHEMBL11855115 0.73 NPC1 (0.42) KDM4EALDH1A1HPGDGAACYP2A6
SCHEMBL14191688 0.73 CYP3A4 (0.49) KDM4EALDH1A1HPGDGAACYP2A6
SCHEMBL3031435 0.72 ALDH1A1 (0.41) KDM4EALDH1A1HPGDGAACYP2A6
SCHEMBL22159520 0.72 KDM4E (0.30) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142692-A1 ANTIFOLATE COMBINATIONS CHELSEA THERAPEUTICS, INC. 2012-06-07 US disclosed
US-20090253719-A1 CRYSTALLINE SALT FORMS OF ANTIFOLATE COMPOUNDS AND METHODS OF MANUFACTURING THEREOF CHELSEA THERAPEUTICS, INC. 2009-10-08 US disclosed
US-7396952-B2 Process for preparing carbamic ester derivatives LANXESS DEUTSCHLAND GMBH (DE) 2008-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142692-A1 ANTIFOLATE COMBINATIONS DHFR, MTX1, MTHFD1 KDM4E 1152/4885ALDH1A1 316/4885HPGD 1121/4885
US-20090253719-A1 CRYSTALLINE SALT FORMS OF ANTIFOLATE COMPOUNDS AND METHODS OF MANUFACTURING THEREOF SLC7A1, SLC10A1, SLC10A6 KDM4E 2180/4885ALDH1A1 1572/4885HPGD 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.